News

iTeos Therapeutics to Present at the 2017 BIO CEO & Investor Conference

Gosselies, Belgium – February 10, 2017 – iTeos Therapeutics SA, a Belgian privately-held biotechnology company applying its expertise in translational tumor immunology to the development of novel cancer immunotherapies, today announced that Michel Detheux, iTeos’ Chief Executive Officer, will present at the 2017 BIO CEO & Investor Conference on Tuesday, February 14 2017 at 10:45 a.m. ET in Park North at The Waldorf Astoria in New York, NY.

Read more

iTeos Therapeutics Announces Opening of New Corporate Headquarters

Gosselies, Belgium – November 28, 2016 – iTeos, a biotechnology company applying its expertise in translational tumor immunology to the development of novel cancer immunotherapies, announced today that it has completed the relocation of its 39 employees into a newly rebuilt, 1,500 square meter (16,200 square foot) corporate headquarters which now houses iTeos’ offices and laboratories. The new facilities are in the EOLE building located at Rue des Frères Wright 29, 6041 Gosselies, Belgium.

Read more

iTeos announces New Target Collaboration and Biowin Grant Award for the Identification of New Immune-Oncology Targets

Gosselies, Belgium - October 24, 2016 — iTeos Therapeutics S.A, together with ChemCom S.A., ImmunXperts S.A., the de Duve Institute and IRIBHM have been awarded 1,6 million euro grant through a BioWin project called IT-Targets. The aim of this collaboration is to identify innovative drug candidates and biomarkers for immunotherapy of various types of cancer, starting from patient tumor derived material. The IT-Targets project will focus on G protein-coupled receptors (GPCRs), which will be selected by profiling the most important immune cell types purified from clinical samples.

Read more